Interpretation of clinical endpoints in trials of acute myeloid leukemia

Although a few new drugs have been approved for acute myeloid leukemia (AML) based on improved survival vs standard therapy in the past 2 decades, the therapeutic landscape is currently poised to expand, with several new agents anticipated to be approved by the US Food and Drug Administration (FDA) in 2017 [1]. Midostaurin, a multitargeted fms-like tyrosine kinase 3 inhibitor, was approved by the FDA in April 2017 [2]. Enasidenib, an isocitrate dehydrogenase 2 –targeted inhibitor; CPX-351, a liposomal daunorubicin/cytarabine combination; and gemtuzumab ozogamicin, a CD33-directed antibody-drug conjugate, were FDA approved in August and September 2017 [3–5].
Source: Leukemia Research - Category: Hematology Authors: Source Type: research